Korea-based Dong-A Pharmaceutical Co. Ltd., will distribute Zydena®, its new oral tablet for erectile
dysfunction (ED) in Saudi Arabia, Oman, Bahrain, Kuwait, UAE and Qatar under a supply and distribution
agreement with SCP. This new agreement with SCP will position Zydena® to effectively compete in this
region with Viagra (Pfizer), Cialis (Lilly) and Levitra (Bayer).




The company claims that Zydena® was launched in Korea in December 2005 and has already exceeded
more than 20% (by volume) of the Korean market due to its excellent efficacy and safety profile.




Dr. Won-Bae Kim, the President of Dong-A Pharmaceutical, stated, “We are extremely pleased with this new
supply and distribution agreement with SCP. We are confident that this new relationship in the Middle East will
significantly expand our market for Zydena® and add to the success that we have already experienced in
Korea. Zydena® sales in Korea have been strong due to its superior efficacy, low adverse event rate and
patient preferred long duration.”